Inhibition or stimulation of immediate, spontaneous rosette formation at various SRBC:lymphocyte ratios.
The active rosette-forming cell (ARFC) percentage was investigated in a group of 100 persons, consisting of 50 healthy blood donors, 30 cancer patients (CA), and 20 patients suffering from rheumatoid arthritis (RA). The test was repeatedly performed using five SRBC:lymphocyte ratios: 10:1, 20:1, 5-:1, 100:1, and 200:1. In 18% of healthy donors and 30-40% of cancer patients, contrary to the remaining persons no relation between ARFC percentage and the SRBC:lymphocyte ratio was found. The "optimal" SRBC:lymphocyte ratio, varied from group to group and was 20:1 for most of RA patients, 50:1 for most of CA patients and 100:1 for most of healthy people. Sometimes, at higher SRBC:lymphocyte ratios a significant lowering of the ARFC percentage was found in relation to the optimal proportion for a given person, and this was observed for 200:1 ratio in 68% of healthy people, 54% of cancer patients and 90% of patients with RA. It is suggested, that ARFC test should be always performed at least in these three SRBC:lymphocyte ratios. Inhibition or stimulation of rosette formation by supernatant fluids of lymphocytes and SRBC suggest that SRBC release substances, which can directly or indirectly inhibit or stimulate rosette formation.
D000328:Adult; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology; D001984:Bronchial Neoplasms / Q000276:immunology; D004906:Erythrocyte Count; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006689:Hodgkin Disease / Q000276:immunology; D006801:Humans; D007114:Immunization; D007166:Immunosuppressive Agents; D007958:Leukocyte Count; D008297:Male; D008545:Melanoma / Q000276:immunology; D008875:Middle Aged; D012397:Rosette Formation / Q000379:methods*; D012756:Sheep; D012878:Skin Neoplasms / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D007166:Immunosuppressive Agents